{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:38:25Z","timestamp":1777865905297,"version":"3.51.4"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,13]]},"DOI":"10.7759\/cureus.43402","type":"journal-article","created":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T09:52:20Z","timestamp":1691920340000},"source":"Crossref","is-referenced-by-count":5,"title":["Pembrolizumab-Induced Eruptive Keratoacanthomas and Lichen Planus in a Lung Cancer Patient"],"prefix":"10.7759","author":[{"given":"Yazmeen","family":"Tembunde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marthe N","family":"Dika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features","volume":"83","author":"Ellis SR","year":"2020","unstructured":"Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M. Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features. J Am Acad Dermatol. 2020, 83:1130-43. 10.1016\/j.jaad.2020.04.105","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000518313","article-title":"Skin deep: a fascinating case report of immunotherapy-triggered, treatment-refractory autoimmune lichen planus and keratoacanthoma","volume":"14","author":"Preti BT","year":"2021","unstructured":"Preti BT, Pencz A, Cowger JJ, Vincent MD, Breadner D. Skin deep: a fascinating case report of immunotherapy-triggered, treatment-refractory autoimmune lichen planus and keratoacanthoma. Case Rep Oncol. 2021, 14:1189-93. 10.1159\/000518313","journal-title":"Case Rep Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.12788\/cutis.0160","article-title":"Hypertrophic lichen planus-like eruption following pembrolizumab","volume":"107","author":"Chapman S","year":"2021","unstructured":"Chapman S, Ashack K, Dapprich DC. Hypertrophic lichen planus-like eruption following pembrolizumab. Cutis. 2021, 107:E10-1. 10.12788\/cutis.0160","journal-title":"Cutis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.11.033","article-title":"Keratoacanthoma (KA): an update and review","volume":"74","author":"Kwiek B","year":"2016","unstructured":"Kwiek B, Schwartz RA. Keratoacanthoma (KA): an update and review. J Am Acad Dermatol. 2016, 74:1220-33. 10.1016\/j.jaad.2015.11.033","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors : skin toxicities and immunotherapy","volume":"19","author":"Sibaud V","year":"2018","unstructured":"Sibaud V. Dermatologic reactions to immune checkpoint inhibitors : skin toxicities and immunotherapy. Am J Clin Dermatol. 2018, 19:345-61. 10.1007\/s40257-017-0336-3","journal-title":"Am J Clin Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi VJ","year":"2016","unstructured":"Shi VJ, Rodic N, Gettinger S, et al.. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol. 2016, 152:1128-36. 10.1001\/jamadermatol.2016.2226","journal-title":"JAMA Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman GJ","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, et al.. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000, 192:1027-34. 10.1084\/jem.192.7.1027","journal-title":"J Exp Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/173815-pembrolizumab-induced-eruptive-keratoacanthomas-and-lichen-planus-in-a-lung-cancer-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:51Z","timestamp":1707508911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/173815-pembrolizumab-induced-eruptive-keratoacanthomas-and-lichen-planus-in-a-lung-cancer-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,13]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.43402","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,13]]}}}